Wells Fargo Maintains Overweight on Rapport Therapeutics, Lowers Price Target to $47
Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweight and lowers the price target from $50 to $47.
A big investment bank still likes Rapport Therapeutics but thinks the stock might be worth less money soon. This means the company is doing okay, but investors should watch if the stock price goes down.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.